Výsledky vyhledávání - "M Nazim Abbas"

Akademický článek

Autor: M. Nazim Abbas, Wei Son Tan, Ganessan Kichenadasse

Publikováno v: Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-5 (2021)

Abstract Background Sorafenib is an oral multikinase inhibitor that targets Raf serine/threonine receptor tyrosine kinases and inhibits tumor cell growth and angiogenesis. Cutaneous toxicities of sorafenib are common, including cutaneous eruptions (s

Externí odkaz: https://doaj.org/article/cfcc5524f4ca429da7954a98d7120328

Zobrazit plný text záznamu

Akademický článek

Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer

Autor: M. Nazim Abbas, Myron Klevansky, Bogda Koczwara, Amitesh Chandra Roy, Shawgi Sukumaran, Sina Vatandoust, Christos Stelios Karapetis

Publikováno v: Cancer Reports, Vol 5, Iss 3, Pp n/a-n/a (2022)

Abstract Background Nivolumab improves disease control and survival in advanced NSCLC in patients with good performance status (PS), but there is limited data on its efficacy in patients with poor PS. Aim Primary objective of the study was to evaluat

Externí odkaz: https://doaj.org/article/780ffd93d8ec4f52b293d9ebe91990d5

Zobrazit plný text záznamu

Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma

Autor: Amitesh Chandra Roy, M. Nazim Abbas, Timothy Jay Price, Nimit Singhal, Sina Vatandoust, John Leung, Ganessan Kichenadasse, Bogda Koczwara, Shawgi Sukumaran, Rajiv Kumar, Richard Woodman, Alex Scott-Hoy, Christos Stelios Karapetis

Publikováno v: Pancreas. 51:490-495

Nab-paclitaxel has radiosensitizing antitumor efficacy in pancreatic cancer. We aimed to establish maximum tolerated dose (MTD) of nab-paclitaxel with radiotherapy in unresectable locally advanced pancreatic cancer.In a phase I dose escalation trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c695571645ebaaaa0dfc16ea1e7c7843
https://doi.org/10.1097/mpa.0000000000002065

Zobrazit plný text záznamu

Patterns of care and outcomes for gastric and gastro‐oesophageal junction cancer in an Australian population

Autor: Jeff Bull, Christos S. Karapetis, Amitesh Roy, Sarah K. Thompson, Timothy J. Price, Caroline Connell, Nimit Singhal, M. Nazim Abbas, David I. Watson, Mary Barnes, Tim Bright

Publikováno v: ANZ Journal of Surgery. 91:2675-2682

BACKGROUND A single state-wide upper gastrointestinal (GI) cancer video-linked multidisciplinary team (MDT) meeting guides management and evidence-based care for all newly diagnosed upper GI cancer patients in South Australia. This study determined t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de06f9c4318f0c864e1bcb2841d38fa
https://doi.org/10.1111/ans.17249

Zobrazit plný text záznamu

Autor: Wei Son Tan, M. Nazim Abbas, Ganessan Kichenadasse

Publikováno v: Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-5 (2021)
Journal of Medical Case Reports

Background Sorafenib is an oral multikinase inhibitor that targets Raf serine/threonine receptor tyrosine kinases and inhibits tumor cell growth and angiogenesis. Cutaneous toxicities of sorafenib are common, including cutaneous eruptions (such as tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9f2e14065cfdc235f0d6e57eb41ed8
https://doaj.org/article/cfcc5524f4ca429da7954a98d7120328

Zobrazit plný text záznamu

Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer

Autor: Myron Klevansky, Shawgi Sukumaran, Bogda Koczwara, Christos S. Karapetis, M. Nazim Abbas, Sina Vatandoust, Amitesh Roy

Publikováno v: Cancer Reports. 5

Background Nivolumab improves disease control and survival in advanced NSCLC in patients with good performance status (PS), but there is limited data on its efficacy in patients with poor PS. Aim Primary objective of the study was to evaluate the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad6d4dbdc96f01e7064c92cfe954aa48
https://doi.org/10.1002/cnr2.1487

Zobrazit plný text záznamu

Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up

Autor: Alison Richards, Shahid Ullah, M. Nazim Abbas, Christos S. Karapetis, Amitesh Roy, Adeola Ayoola, Bogda Koczwara, John Leung, Shawgi Sukumaran, Rajiv Kumar, Ganessan Kichenadasse, Sunita Padman, Jeffrey Bowden

Publikováno v: Journal of thoracic disease. 11(10)

Background: The preferred management of patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemo-radiotherapy (CRT). Acute CRT-related toxicities are well defined, however, less is known about late toxicit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b15ba4ea0aa62e5249c14f469050fcb
https://pubmed.ncbi.nlm.nih.gov/31737309

Zobrazit plný text záznamu

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

Autor: Tessa Gargett, Paul Rolan, Joseph G. Altin, Antonio Ferrante, Michael P. Brown, Ines Atmosukarto, Katharine M. Gosling, M. Nazim Abbas, Christopher R. Parish, Jason D. Price, Andrew Ruszkiewicz

Publikováno v: Cancer immunology, immunotherapy : CII. 67(9)

Introduction: In this phase I study using a 3 + 3 dose escalation design, the safety, dose-limiting toxicity (DLT), immunogenicity and efficacy of intravenous Lipovaxin-MM—a multi-component dendritic cell-targeted liposomal vaccine against metastat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71caa5d74a0d8612153e8a0464d48d2e
https://pubmed.ncbi.nlm.nih.gov/30014244

Zobrazit plný text záznamu

Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases

Autor: Sina Vatandoust, Tim F Bright, M Nazim Abbas, Amitesh Chandra Roy, David I. Watson, Susan S H Gan, Alex Scott-Hoy, Jeff A Bull, Christos Stelios Karapetis

Publikováno v: Journal of Clinical Oncology. 37:4061-4061

4061 Background: IPP is a potential treatment option in patients with gastric cancer with peritoneal metastasis. IPP with a dose of 20 mg/m2 is well tolerated in combination with S1; however, this has been achieved in a specific genetic pool (Japanes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56f7d6e4c00ac363162ab9b01c944442
https://doi.org/10.1200/jco.2019.37.15_suppl.4061

Zobrazit plný text záznamu

A prospective study of anti-mullerian hormone (AMH) as a predictor of chemotherapy-induced menopause

Autor: Shawgi Sukumaran, Fiona Young, Elinor Atkinson, Christos S. Karapetis, Hilary Martin, Shahid Ullah, Muhammad A. Khattak, David M. Ross, Ganessan Kichenadasse, Amitesh Roy, Bogda Koczwara, M. Nazim Abbas, Alex Scott-Hoy

Publikováno v: Journal of Clinical Oncology. 37:e23076-e23076

e23076 Background: Chemotherapy-induced premature menopause is a distressing side effect of cancer treatment. Currently there are no validated tools to predict the loss of ovarian function. Anti-Mullerian hormone (AMH) in healthy women correlates wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02200531df3d2245abb01417f7bc0fa7
https://doi.org/10.1200/jco.2019.37.15_suppl.e23076

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání